{"filing":{"accession_number":"0001140361-26-040506","cik":"0001124105","ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-16","primary_document":"ef20080299_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126040506/ef20080299_8k.htm"},"events":[{"id":37183,"run_id":34281,"accession_number":"0001140361-26-040506","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses employment agreements with two named executives (CEO Ying Luo and CFO Thomas Eastling) that establish compensatory arrangements including base salary, annual bonus targets, severance provisions, COBRA reimbursement, and accelerated equity vesting upon termination or change of control. While the agreements also confirm continued service, the substantive disclosure centers on the compensation terms and severance/change-of-control benefits, which is the hallmark of exec_compensation under Item 5.02(e).","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41818,"accession_number":"0001140361-26-040506","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses employment agreements with two named executives (CEO Ying Luo and CFO Thomas Eastling) that establish compensatory arrangements including base salary, annual bonus targets, severance provisions, COBRA reimbursement, and accelerated equity vesting upon termination or change of control. While the agreements also confirm continued service, the substantive disclosure centers on the compensation terms and severance/change-of-control benefits, which is the hallmark of exec_compensation under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:03:44.919652+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41818,"accession_number":"0001140361-26-040506","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses employment agreements with two named executives (CEO Ying Luo and CFO Thomas Eastling) that establish compensatory arrangements including base salary, annual bonus targets, severance provisions, COBRA reimbursement, and accelerated equity vesting upon termination or change of control. While the agreements also confirm continued service, the substantive disclosure centers on the compensation terms and severance/change-of-control benefits, which is the hallmark of exec_compensation under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:03:44.919652+00:00","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-10-22"}]}